Selected data models

You must log in to select data models for download or further analysis.

8 Search results.
Relevance Rating New first Old first

Eligibility Type 2 Diabetes NCT00612794

- 6/13/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00612794

Eligibility Type 2 Diabetes Mellitus NCT02004886

- 6/13/17 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005); ODM derived from: https://clinicaltrials.gov/show/NCT02004886

Eligibility Type 2 Diabetes Mellitus NCT00605475

- 6/13/17 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00605475

Prior Ocular Therapies And Procedures Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4170g - Prior Ocular Therapies And Procedures Screening

- 3/21/18 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Therapy diabetes mellitus
Study part: Prior Ocular Therapies And Procedures Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Prior Ocular Therapies And Procedures Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4168g - Prior Ocular Therapies And Procedures Screening

- 3/20/18 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Therapy diabetes mellitus
Study part: Prior Ocular Therapies And Procedures Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12) CRFs Roche FVF4170G Macular Edema NCT00473382

- 6/11/17 - 1 form, 3 itemgroups, 12 items, 1 language
Itemgroups: Patient administration, CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12), Procedure
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12) CRFs Roche FVF4168G Macular Edema NCT00473330

- 6/11/17 - 1 form, 3 itemgroups, 12 items, 1 language
Itemgroups: Patient administration, CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12), Procedure
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Common Data Elements for Retinal Neovascular Diseases - Risk Factors or Past Medical History

- 9/20/21 - 4 forms, 1 itemgroup, 35 items, 2 languages
Itemgroup: Risk Factors; Past Medical History
Common Data Elements for retinal neovascular diseases. The CDEs may be used in clinical routine, clinical trial, patient outcome, quality assurance and registry documentation of Age related macular degeneration (AMD), Diabetic Retinopathy (DR) and Retinal vein occlusion (RVO). The CDEs were developed by the Institute of Medical Informatics of the University Muenster in cooperation with the Department of Ophthalmology of the University Hospital Muenster.

Diagnosis and Examination

1 itemgroup 11 items

Eye Examination

1 itemgroup 18 items

Therapy

1 itemgroup 9 items

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial